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Summary
Inhibitors for matrix metalloproteinases (MMPs) are
under investigation for the treatment of cancer, arthri-
tis, and cardiovascular disease. Here, we report a
class of highly selective MMP-13 inhibitors (pyrimi-
dine dicarboxamides) that exhibit no detectable activ-
ity against other MMPs. The high-resolution X-ray
structures of three molecules of this series bound to
MMP-13 reveal a novel binding mode characterized by
the absence of interactions between the inhibitors
and the catalytic zinc. The inhibitors bind in the S1
pocket and extend into an additional S1 side pocket,
which is unique to MMP-13. We analyze the determi-
nants for selectivity and describe the rational design
of improved compounds with low nanomolar affinity.
Introduction
Matrix metalloproteinases (MMPs) are a family of zinc
endopeptidases that degrade proteins of the extracel-
lular matrix, including collagens, elastins, matrix glyco-
proteins, and proteoclycans [1, 2]. Zymogen activation
and endogenous tissue inhibitors of matrix metallopro-
teinases (TIMPs) control MMP activity during normal
morphogenesis and tissue homeostasis. Abnormal ex-
pression or activity of MMPs has been associated with
pathological processes related to metastasis, angio-
genesis, and cardiovascular disease, as well as rheu-
mathoid arthritis and osteoarthritis [3].
The approximately 27 currently known human MMPs
can be grouped into subfamilies based on their sub-
strate specificity [4, 5]. Enzymes of the collagenase
family (MMP-1, -8, and -13) cleave fibrillar collagens at
neutral pH. MMP-13 cleaves type II collagen more
rapidly than MMP-1 or MMP-8 [6]. Along with enhanced
MMP-13 mRNA levels in osteoarthritic joints and breast
carcinomas, this provides the rationale for MMP-13 as
an attractive target for the treatment of degenerative
joint disease and breast cancer [4, 7–9].
Clinical administration of broad-spectrum MMP in-
hibitors, e.g., marimastat, has disclosed severe adverse
effects, such as musculoskeletal pain and tendonitis
[10]. Consequently, research has been focused on se-
lective inhibition of those MMPs implicated in the
targeted disease pathology [11, 12]. While a number of
compounds have been identified that exhibit preferen-
tial inhibition of certain MMPs, exclusive inhibition of a*Correspondence: ulrich.wendt@sanofi-aventis.comsingle MMP has been much more difficult to achieve
[5, 13].
At present, the affinity of most known MMP inhibitors
relies on two dominant molecular features: (1) a chelat-
ing moiety that interacts with the catalytic zinc ion (e.g.,
hydroxamate groups) and (2) hydrophobic extensions
protruding from the catalytic site into the large and hy-
drophobic S1# pocket (P1# group) [14]. Since the struc-
tural differences between MMP family members occur
mainly in the S1# subsite, modifications of the P1#
group have been utilized to introduce inhibitor specific-
ity [5, 15]. In particular, the nature of amino acid 218
(MMP-13 numbering) and the so-called specificity loop
(amino acids 244–255), which surrounds the zinc-distal
part of the S1# pocket, are discussed as determinants
of specificity [16–18].
Among the known zinc-chelating moieties, the hydro-
xamate group has often been selected as the function-
ality of choice [19], but has been correlated to unfavor-
able pharmacokinetics [20] and may be related to
chronic toxicity resulting from metabolic activation of
the hydroxamate function. These findings have led to
the search for alternate zinc binding groups [19, 21–23].
Recently, Chen et al. [15] have described micromolar
inhibitors that occupy the S1# pocket of MMP-13 with-
out interacting with the catalytic zinc. However, opti-
mizing these inhibitors to low nanomolar affinities re-
quired the introduction of a zinc binding moiety and
yielded a selectivity of >5800-, 56-, and >500-fold
against MMP1, MMP9, and TACE [15].
Here, we report on pyrimidine dicarboxamides, a
class of highly selective MMP-13 inhibitors exemplified
by compound 1 (Figure 1). The crystal structure of 1
bound to the catalytic domain of MMP-13 reveals a
binding mode that is characterized by the absence of
interactions between 1 and the catalytic zinc. A related
pharmacophore model has been suggested [24].
Based on our crystal structure, the selectivity of 1 is
investigated by comparison with known MMP struc-
tures, and the unusual binding mode of 1 is exploited to
design selective non-zinc-chelating inhibitors with low
nanomolar activity.
Results and Discussion
Activity Assays
Pyrimidine dicarboxamide 1 exhibited good activity
against MMP-13 (IC50 = 6.6 M) and no detectable inhi-
bition of any other tested enzyme (MMP-1, -2, -3, -7,
-8, -9, -10, -12, -14, -16; detection limit at 100 M). In
addition, 1 exhibits good water solubility (500 M at pH
7.5) and a reasonable oral bioavailability in rats (50%).
These properties made the pyrimidine dicarboxamide 1
a promising candidate for further optimization.
Crystal Structures
The crystal structure of 1 in complex with the catalytic
domain of MMP-13 (MMP-13cd) was determined to in-
vestigate the relationship between the molecular struc-
ture of 1 and its high selectivity. Crystals were prepared
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sFigure 1. Pyrimidine Dicarboxamide Inhibitors of MMP-13
1, IC50 = 6600 nM; 2, IC50 = 400 nM; 3, IC50 = 72 nM; 4, IC50 = 8 nM. t
Baccording to the protocol of Lovejoy et al. [16]. Crystal- c
lographic results are summarized in Table 1. i
sThe 1.85 Å cocrystal structure of 1 reveals a binding tructures (PDB entries 1FM1 and 1EUB [25]) suggests
Table 1. Crystallographic Data
Compound 1 Compound 3 Compound 4
Data processing
Resolution (Å) (last shell) 1.85 (1.90–1.85) 1.70 (1.80–1.70) 1.80 (1.90–1.80)
Space group C2 C2 C2
Asymmetric unit two monomers two monomers two monomers
Cell constants a, b, c (Å); β (°) 134.5, 36.5, 95.6; 130.5 134.4, 36.5, 95.3; 130.5 134.0, 36.5, 95.1; 130.4
Total reflections 107,204 133,888 108,348
Unique reflections 30,251 38,478 30,796
Rsym (%)a 3.5 (7.1) 5.2 (10.3) 5.2 (10.1)
Completeness (%) 98.4 (90.0) 97.8 (90.5) 93.0 (60.9)
Mean I/σ 22.4 (10.7) 14.7 (8.2) 17.7 (8.6)
Refinement
Rcryst (%)b 16.6 17.2 16.8
Rfree (%)c 20.2 20.0 20.3
Rmsd bonds (Å) 0.0046 0.0043 0.0044
Rmsd angles (°) 1.19 1.18 1.18
No. of protein atoms 2,675 2,675 2,675
No. of solvent atoms 489 445 473
No. of ligand atoms 2 × 26 2 × 28 2 × 30
a Rsym(I) = ShklSi|Ihkl,i − <Ihkl>|/ShklSi|Ihkl,i| × 100, for all independent reflections and i observations of a given reflection. <Ihkl> is the mean
intensity of the i observations.
b Rcryst = S|Fo − Fc|/SFo × 100, where Fo and Fc are observed and calculated structure factors, respectively.
c Rfree is the crossvalidation R factor computed for a test set of reflections (5% of the total), which are omitted in the refinement process.ode that has not been observed for other MMP inhibi-
ors. It is characterized by the absence of interactions
etween the inhibitor and the catalytic zinc (Figure 2A).
he inhibitor binds deeply in the S1# pocket of MMP-
3 from which it protrudes into a side pocket of S1#
hat has not been described for other MMPs and is re-
erred to as the S1#* pocket (Figure 2B). The pyridyl
ubstitution closer to the active site (proximal arm)
oints toward the entrance of the S1# pocket and does
ot approach the catalytic zinc closer than 5.5 Å. The
yridyl substitution pointing away from the catalytic
inc (distal arm) protrudes from the S1# pocket into the
djacent S1#* pocket. Overall, 1 exhibits a bent confor-
ation in which the central pyrimidine dicarboxamide
caffold is tightly packed onto the side chain of Leu218,
hile the two pyridyl substitutions are embracing the
eu218 side chain like gripping pliers (Figure 3A). The
xo groups of the central scaffold form hydrogen
onds with the main chain of Thr245 and Thr247 and
he side chain of Thr247 in the specificity loop (Figures
A and 3B). The nitrogens of both pyridyl rings form
ydrogen bonds with well-defined water molecules
Figure 3A). Of these, the water at the zinc-distal site of
he inhibitor forms hydrogen bonds with the protein,
hile the water at the proximal side lies in a network of
ell-defined structural water.
Overall, the central scaffold and the distal pyridyl
roup of 1 form intricate interactions with the specific-
ty loop of MMP-13, which defines the shape and size
f the S1#* pocket. Correspondingly, the complex struc-
ures of MMP-13cd with pyrimidine dicarboxamides (1,
, 4) exhibit continuous and well-defined electron den-
ity for this loop and the inhibitors. A comparison with
he two publicly available X-ray structures (Protein Data
ank [PDB] entries 830C and 456C [16]), 16 further
omplex structures with nonpyrimidine dicarboxamide
nhibitors (C.K.E., unpublished data), and two NMR
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183Figure 2. Binding Mode of Pyrimidine Dicarboxamides Exemplified by Inhibitor 1
(A) Stereo graphic of MMP-13cd (gray ribbon representation). The catalytic zinc (yellow sphere), the specificity loop (yellow ribbon), inhibitor
1 (magenta), and Leu218 (gold) are highlighted. Inhibitor 1 is binding without contacting the catalytic zinc, deeply within the S1# pocket,
where it packs onto Leu218 and extends into the S1#* pocket. For comparison, the zinc-chelating hydroxamate MMP-inhibitor RS-130830
(light blue) was superimposed from PDB entry 830c [16].
(B) Molecular surface of MMP-13cd in a similar orientation. The surface is color coded with carbon atoms shown in gray, oxygen, red;
nitrogen, blue; and sulfur, yellow. At left is shown the molecular surface with the hydroxamate inhibitor RS-130830 visible at the active site.
On the opposite side of the molecule, the back entrances of the S1# pocket and the S1#* pocket are depicted with arrows. At right is shown
the cut molecular surface. The cutting plane opens the view onto S1# and S1#* with 1 and superimposed RS-130830.that the specificity loop of MMP-13 exhibits significant
flexibility when it is not in contact with inhibitors like 1
[16, 25]. Inhibitor 1, therefore, appears to select a par-
ticular specificity loop conformation from a conforma-
tional ensemble in apo MMP-13.
Selectivity against Other MMPs
In order to analyze the structural determinants for the
MMP-13 selectivity of pyrimidine dicarboxamide inhibi-
tors, the structures of 11 MMP catalytic domains with
published three-dimensional structure (MMP-1, -2, -3,
-7, -8, -9, -10, -11, -12, -14, and -16 [16, 17, 26–40])
were superimposed with the complex structure of
MMP-13 and 1 (Figures 4 and 5). Visual inspection of
the superposition and the inhibitor binding pocket sug-
gests the nature of the residue in position 218 (MMP-
13 numbering) and the sequence and conformation ofthe MMP-specificity loop as determinants for the MMP
selectivity of 1.
The X-ray structures show that the packing interac-
tion of 1 with Leu218 is critical for the formation of the
inhibitor complex (Figure 3A). Most MMPs carry a leu-
cine residue in the position equivalent to Leu218 in
MMP-13 as well. However, MMP -1, -7, and -11 carry
bulkier residues in position 218 (Figure 4), which would
prohibit complex formation due to steric hindrance.
The particular conformation that the specificity loop
of MMP-13 assumes in the complex with 1 is critical for
inhibitor binding, since it (1) determines the shape and
size of the S1#* pocket, which accommodates the distal
arm of 1 (Figure 2B), and (2) determines the exact ge-
ometry of polar interactions between the specificity
loop and the inhibitor (Figure 3). To investigate the role
of the specificity loop conformation for MMP selectivity
Chemistry & Biology
184Figure 3. Protein/Inhibitor Interactions
(A) Ribbon representation of MMP-13cd (gray). The inhibitor and several residues are highlighted in stick representation. The side chains of
Tyr244 and Tyr246 have been omitted for clarity. Polar interactions are depicted as dashed lines. The 2Fo-Fc electron density is contoured at
2 σ and shown in green. Two structural water molecules are shown in red.
(B) Sketch of polar interactions between 1 and the catalytic domain of MMP-13. Distances are indicated for the two monomers in the
asymmetric unit (chain B in parentheses)of 1, we inspected the superposition of MMP-13 with H
ithe 11 MMP catalytic domains of known three-dimen-
sional structure. As observed for MMP-13, other MMPs t
ialso exhibit at least some flexibility in the specificity
loop region. Accordingly, 6 of 110 crystallographically b
nindependent MMP chains in the PDB exhibit disorder
(discontinuous coordinate sets) for the specificity loop. oowever, it is interesting to observe that for the remain-
ng 104 chains with continuous coordinate sets none of
he observed specificity loop conformations is compat-
ble with the steric and geometric requirements for
inding of 1, as exemplified in Figure 5. While we can-
ot exclude that other MMPs can assume currently un-
bserved conformations, our biochemical data suggest
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185Figure 4. Structure-Based Sequence Align-
ment of MMPs with Known Three-Dimen-
sional Structure
The region shown corresponds to residues
212–265 of MMP-13 and contains Leu218
(cyan), the catalytic histidines (red), and the
specificity loop (residues 244–255, yellow)
with Gly248.that the conformational space of the MMP-13 specific-
ity loop is not accessible for other MMPs. Conforma-
tional restrictions appear obvious for those MMPs with
specificity loops shorter than that of MMP-13 (Figure
5A), whereas conformational restrictions for MMPs with
similar or longer specificity loops must be based on
the loops’ sequence. In complex with pyrimidine di-
carboxamide inhibitors, Gly248 in the specificity loop
of MMP-13 assumes a main-chain conformation, which
is energetically disfavored for nonglycine residues. We
propose that conformational flexibility in this position is
crucial for the hydrogen bonding geometry between 1
and the neighboring residues Thr247 and Thr245 (Fig-
ure 3). Accordingly, those MMPs that carry a nonglycine
residue in an equivalent position may not be able to
assume a specificity loop conformation compatible
with the binding of 1 (Figure 4).
Overall, this analysis supports the observed selectiv-
ity against MMP -1, -2, -3, -7, -8, -9, -10, -12 -14, and
-16 (no detectable affinity with detection cutoff at 100
M) and strongly suggests similar selectivity against
MMP-11 (glutamine in position 218).
Inhibitor Design
For the design of improved analogs of 1 (IC50 = 6.6 M),
we analyzed molecular properties of the binding
pocket. To start with, we considered the central pyrimi-
dine dicarboxamide moiety as a key anchoring point
and kept it invariant. From a synthetic chemistry point
of view, the scaffold is amenable to parallel synthesis
by coupling the pyrimidine dicarboxamide core to
amine building blocks. Instead of synthesizing large
compound libraries, we decided to use the crystal
structures to probe interactions with a limited number
of amines. Our design strategy included three steps,
which are exemplified by inhibitors 2–4: (1) the replace-
ment of the relatively polar pyridyl substitutions with
less polar residues, (2) probing potential entropy gains
from displacement of structural water around the pyri-
dyl nitrogens of 1, and (3) optimizing van der Waals in-
teractions with side chains in the vicinity of the inhibitor.
Closer inspection of the inhibitor interactions with
MMP-13 reveals a π-stacking interaction between the
proximal pyridine of 1 and His222, while the distal pyri-
dine of 1 is involved in interactions with a cluster of
lipophilic side chains from Phe217, Leu218, Tyr246, and
Phe252. Together, these observations suggested prob-
ing nonpolar aromatic replacements of the pyridyl of 1,
as exemplified by the benzyl analog 2, which exhibitedan activity increase of 1.5 orders of magnitude (IC50 =
400 nM).
As a second step, we probed substitutions at the
benzyl group in order to displace the structural water
and increase hydrophobic interactions at the outer
rings of the inhibitor. Inhibitor 3 (IC50 = 72 nM) has a
methyl group pointing in the direction of the structural
water seen in our original structure (Figure 3). A com-
parison of the X-ray structures of MMP-13cd in com-
plex with 1 and 3 provided a detailed view of the water
structure around the inhibitor binding site. At the proxi-
mal site, the replacement of the pyridyl substitution in
1 by a methyl-benzyl group in 3 leads to a net displace-
ment of two structural water molecules from the protein
inhibitor complex (Figure 6). At the distal site, the same
substitution results in a shift of one structural water
without altering the net sum of structural waters around
the inhibitor.
As a third step, the addition of a fluoro group in inhib-
itor 4 led to an improved IC50 of 8 nM, which likely re-
sults from improved interactions with residues Leu185,
Val219, and Asp223 at the proximal site and Lys140,
Asn215, and Phe217 at the distal site. The complex
structure with 4 shows that the net sum of structural
water around the inhibitor is unchanged with respect to
compound 3 (Figure 6).
Significance
Matrix metalloproteinases (MMPs) are a family of zinc
endopeptidases involved in the homeostasis of the
extracellular matrix. Abnormal activity of these en-
zymes has been related to a variety of pathologic pro-
cesses, involving metastasis, angiogenesis, cardio-
vascular disease, osteoarthritis, and rheumathoid
arthritis [3]. The development of potent subclass-
selective inhibitors of these enzymes has been chal-
lenging, and most described inhibitors rely on a small
number of zinc binding motifs [5]. The X-ray struc-
tures reported in this paper reveal a class of highly
selective inhibitors of MMP-13 that do not interact
with the catalytic zinc but bind deeply in the S1
pocket of MMP-13, from which they protrude into a
side pocket (S1*) that has not been observed in
other MMPs.
A structural alignment with the catalytic domains of
11 MMPs suggests the nature of the residues in posi-
tion 218 and 248 as well as the sequence and confor-
mation of the specificity loop (residues 244–255 in
Chemistry & Biology
186Figure 5. Comparison of MMP Structures
The complex structure with 1 is depicted invariantly with the protein Cα-trace (red), inhibitor 1 (magenta), and the corresponding van der
Waals surface of the inhibitor (dots). The specificity loop in MMP-13 has a length of 11 residues.
(A) Superposition of MMP-13 with MMPs with shorter specificity loops: MMP-1 (blue, nine residues), MMP-2 (green, nine residues), MMP-9
(pink, nine residues), and MMP-11 (yellow, nine residues).
(B) Superposition of MMPs with specificity loops of identical length, as in MMP-13: MMP-7 (blue), MMP-8 (green), MMP-12 (cyan), MMP-14
(yellow), and MMP-16 (pink).
(C) Superposition with MMPs with longer specificity loops: MMP-10 (green, 12 residues) and two distinct loop conformations of MMP-3 (blue
and cyan, 12 residues).
Non-Zinc Binding Selective MMP-13 Inhibitors
187Figure 6. Water Networks at the Proximal Site
A stereo graphic of MMP-13 (gray ribbon diagram) is shown with the active site histidines (sticks) and the catalytic zinc (yellow sphere).
Superimposed are inhibitors 1 (gray), 3 (orange), and 4 (magenta) and the three corresponding water networks at the proximal site. Water
molecules that are found in almost identical positions in all three structures are colored in bright green. Otherwise, waters are colored
according to the inhibitor complex they belong to: complex with 1, red and cyan; 3, orange; and 4, magenta. The two water molecules from
the complex structure with 1 shown in red are displaced in the complexes with 3 and 4. The two water molecules shown in cyan are shifted
upon binding of 3 or 4 (magenta dashed lines).MMP-13) as structural determinants for the high MMP
selectivity of these molecules. Rational design of in-
hibitors with low nanomolar affinity involved improve-
ment of hydrophobic interactions and the replace-
ment of structural water molecules.
Experimental Procedures
Assays
Pro MMP-13 (G25-C471) was prepared according to the procedure
of Okada et al. [41] (Invitek, Berlin, Germany). Activation of the en-
zyme using 1 mM APMA (4-aminophenymercuric acetate) and sub-
sequent assay of proteolytic activity using a quenched fluorogenic
substrate were performed as described by Knight et al. [42]. Each
well contained 10 µl enzyme (in 0.1 mol/l Tris/HCl [pH 7.5], 0.1 mol/l
NaCl, 0.01 mmol/l CaCl2, 0.015% Brij 35) and 10 µl inhibitor in 3%
DMSO. After preincubation for 15 min at 22°C, the reaction was
started by addition of 10 µl substrate (75 µmol/l in 0.75% DMSO).
Activity measurements for the other MMPs were performed ac-
cording to the procedure described in Matter et al. [43]. Substrates
were (6-(7-nitrobenzyl [1, 2, 5] oxadiazol-4-ylamino)-hexanoyl-arg-
pro-lys-pro-leu-ala-nva-trp-lys-(7dimethylaminocoumarin-4-yl)-NH2
for MMP-10 and (7-methoxycoumarin-4-yl) acetyl-pro-leu-gly-leu-
3-(2#,4#-dinitrophenyl)-L-2,3-diaminopropionyl-ala-arg-NH2 for all
other MMPs. The substrates were purchased from Bachem, Heidel-
berg, Germany. The initial velocity of each enzymatic reaction was
determined without inhibitor (= 100%) and with at least five dif-
ferent inhibitor concentrations. Each assay was run in triplicate,
and IC50 values were calculated based on a four-parameter model
[44]. Bioavailability in rats was determined according to the pro-
cedure described by Matter et al. [45].
Chemistry
The procedure for preparing compounds 1–4 was as follows: py-
rimidine-4,6-dicarboxylic acid (200 mg, 1.2 mmol) was added to
SOCl2 (0.3 ml, 4.1 mmol), and the mixture was stirred at 85°C for 2
hr. The resulting mixture was cooled to room temperature and di-
luted with CH2Cl2 (2 ml). The mixture was further cooled to 0°C,
triethylamine (0.33 ml, 2.4 mmol) and the appropriate amines (5.4
mmol) were added, and the mixture was stirred for 15 min. The
reaction mixture was diluted with CH2Cl2 (10 ml) and water (10 ml).
The organic layer was washed with brine and dried over MgSO .4Removal of the solvent and crystallization from ethyl acetate/hep-
tene (3:1) gave the title compounds.
Pyrimidine-4,6-Dicarboxylic Acid
Bis-[(Pyridin-3-YL-Methyl)-Amide] 1
1H NMR (400 MHz, DMSO-d6)δ 9.80 (m, 2H), 9.45 (s, 1H), 8.58 (m,
2H), 8.45 (m, 3H), 7.75 (m, 2H), 7.35 (m, 2H), 4.55 (m, 4H); MS (ESI)
m/z 348.00 (M+).
Pyrimidine-4,6-Dicarboxylic Acid Bis-Benzylamide 2
1H NMR (400 MHz, DMSO-d6)δ 9.70 (m, 2H), 9.45 (s, 1H), 8.48 (s,
1H), 7.32 (m, 8H), 7.25 (m, 2H), 4.52 (m, 4H); MS (ESI) m/z 346.14
(M+).
Pyrimidine-4,6-Dicarboxylic Acid Bis-(3-Methyl-Benzylamide) 3
1H NMR (400 MHz, DMSO-d6)δ 9.45 (s, 1H), 8.45 (s, 1H), 7.20 (m,
2H), 7.12 (m, 4H), 7.05 (m, 2H), 4.48 (m, 4H), 2.30 (s, 6H); MS (ESI)
m/z 375.13 (M+).
Pyrimidine-4,6-Dicarboxylic Acid
Bis-(4-Fluoro-3-Methyl-Benzylamide) 4
1H NMR (400 MHz, DMSO-d6)δ 9.65 (m, 2H), 9.42 (s, 1H), 8.55 (s,
1H), 7.22 (m, 2H), 7.15 (m, 2H), 7.08 (m, 2H), 4.50 (m, 4H), 2.40 (s,
6H); MS (ESI) m/z 411.25 (M+).
Crystallography
Activated recombinant human MMP-13 catalytic domain (Tyr104-
Asn274) was purchased from Invitek, Berlin, Germany and stored
at −80°C in a solution containing 50 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 5 mM CaCl2. For crystallization, the enzyme was concen-
trated to 10 mg/ml, and crystals were grown by mixing equal vol-
umes of protein and reservoir solution consisting of 0.1 M Tris-HCl
(pH 8.0), 17% (w/v) PEG4000, and 1 M ammonium formate in the
presence of a low-affinity MMP-13 inhibitor [16]. Compounds 1, 3,
and 4 were dissolved in DMSO, and MMP-13cd crystals were
soaked for 1–3 days in the reservoir solution supplemented with
2.5–5 mM inhibitor. The crystals were cryoprotected in the reservoir
solution supplemented with 15% (w/v) PEG400 and flash frozen
in liquid nitrogen. Data were collected at beamlines id14-1 and
id14-2 at the European Synchrotron Radiation Facility (ESRF), Gre-
noble, France and processed with XDS and XSCALE [46, 47]. Struc-
tures were determined by molecular replacement using PDB entry
830C [16] as search model. Molecular replacement, refinement,
and model building were preformed with the programs CNX [48]
and Quanta [49]. The water structures were generated with a semi-
automated procedure using Quanta. Water molecules were in-
cluded based on positive F − F difference density at a 3 σ cutoffo c
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188level and a 1 σ cutoff in 2Fo − Fc electron density maps after subse- 1
quent refinement. Structures were analyzed and visualized with
CCP4 software [50] and Pymol [51].
1
Accession Numbers
1
The coordinates have been deposited in the Protein Data Bank with
accession codes 1XUC, 1XUD, and 1XUR.
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